

S2-Leitlinie zur Diagnostik und Therapie der infektiösen Endokarditis

Christoph K. Naber (1), Artur Bauhofer, Michael Block, Michael Buerke, Raimund Erbel, Wolfgang Graninger, Mathias Herrmann (2), Dieter Horstkotte (3), Peter Kern, Hartmut Lode, Uwe Mehlhorn (4), Jürgen Meyer (5), Andreas Mügge, Jörg Niebel (6), Georg Peters (7), Pramod M. Shah, Karl Werdan (8)

Herausgegeben von der Paul-Ehrlich-Gesellschaft für Chemotherapie (PEG) und dem Vorstand der Deutschen Gesellschaft für Kardiologie, Herz- und Kreislaufforschung (DGK) in Zusammenarbeit mit

der Deutschen Gesellschaft für Thorax-, Herz- und Gefäßchirurgie (DGTHG), der Deutschen Gesellschaft für Infektiologie (DGI), der Deutschen Gesellschaft für Internistische Intensivmedizin und Notfallmedizin (DGIIN), der Deutschen Gesellschaft für Hygiene und Mikrobiologie (DGHM) und der Deutschen Gesellschaft für Innere Medizin (DGIM)

Bearbeitet im Auftrag des Vorstandes der PEG (G. Peters, P. Kern, G. Gross, K. Tröster, M. Kresken, F. Vogel sowie P. M. Shah, U. Ullmann, B. Wiedemann) und der Kommission für Klinische Kardiologie der DGKHK (R.H. Strasser, D. Andresen, G. Ertl, F. de Haan, C.W. Hamm, H. Mudra, A. Osterspey, K. Werdan sowie G. Arnold, H.M. Hoffmeister, E. Fleck, H. J. Trappe)

(1) für die DGK, (2) für die DGI, (3) ESC Task Force, (4) für die DGTHG, (5) für die DGIM, (6) für die PEG, (7) für die DGHM, (8) für die DGIIN

Methodische Beratung: Ina Kopp (Arbeitsgemeinschaft der Wissenschaftlichen Medizinischen Fachgesellschaften, AWMF).

Kommentare und Durchsicht: E. Gams (Düsseldorf), W. Handrick (Frankfurt/Oder), W. Kern (Freiburg), H. Mauch (Berlin), A. Podbielski (Rostock), A.A. Schmaltz (Essen), H. Schrotten (Düsseldorf)

Literatur

- Hoen B, Alla F, Selton-Suty C, Beguinot I, Bouvet A, Briancon S, Casalta JP, Danchin N, Delahaye F, Etienne J, Le Moing V, Lepoint C, Mainardi JL, Ruimy R, Vandenesch F; Association pour l'Etude et la Prevention de l'Endocardite Infectieuse (AEPEI) Study Group. Changing profile of infective endocarditis: results of a 1-year survey in France. *JAMA* 2002;288:75-81.
- Benetka O, Block M, Sangha O, Praetorius F, Gottwik M, Uebis R, Neuhaus KL, v Essen R. On behalf of the ALKK, Arbeitsgemeinschaft Leitender Kardiologischer Krankenhausärzte. Clinical course of infective endocarditis in the late nineties: preliminary results of the ALKK endocarditis registry [abstract]. *Eur Heart J* 1999;20:(Suppl):362.
- Horstkotte D, for the Task Force on Infective Endocarditis of the European Society of Cardiology. Recommendations for prevention, diagnosis and treatment of infective endocarditis. *Eur Heart J* 2004;25:267-76.
- Lorenz W, Ollenschläger G, Geradts M, Gerlach FM, Grandjour A, Helou A. Das Leitlinien-Manual. Entwicklung und Implementierung von Leitlinien in der Medizin. Zeitschrift für ärztliche Fortbildung und Qualitätssicherung 2001;95(Suppl) D.
- The AGREE-Collaboration. Appraisal of Guidelines for Research and Evaluation (AGREE) Instrument. 2003. <http://www.agreecollaboration.org>.
- Trappe HJ. Leitlinien der Deutschen Gesellschaft für Kardiologie – Herz- und Kreislaufforschung. *Z Kardiol* 2003;92:689-93
- Delbecq AL, Van de Ven AH, Gustafson DH. Group techniques for program planning. Glenview, IL, Scott, Foresman and Company, 1975.
- Evangelista A, Gonzalez-Alujas MT. Echocardiography in infective endocarditis. *Heart* 2004;90:614-7.
- Mügge A. Echocardiographic detection of cardiac valve vegetations and prognostic implications. *Infect Dis Clin North Am* 1993;7:877-98.
- Erbel R, Rohmann S, Drexler M, Mohr-Kahaly S, Gerharz CD, Iversen S, Oelert H, Meyer J. Improved diagnostic value of echocardiography in patients with infective endocarditis by transoesophageal approach. A prospective study. *Eur Heart J* 1988;9:43-53.
- Daniel WG, Mugge A, Martin RP, Lindert O, Hausmann D, Nonnast-Daniel B, Laas J, Lichtlen PR. Improvement in the diagnosis of abscesses associated with endocarditis by transoesophageal echocardiography. *N Engl J Med* 1991;324:795-800.
- Piper C, Hetzer R, Korfer R, Bergemann R, Horstkotte D. The importance of secondary mitral valve involvement in primary aortic valve endocarditis; the mitral kissing vegetation. *Eur Heart J* 2002;23:79-86.
- Di Salvo G, Habib G, Pergola V, Avierinos JF, Philip E, Casalta JP, Vailloud JM, Derumeaux G, Gouvernet J, Ambrosi P, Lambert M, Ferracci A, Raoult D, Luccioni R. Echocardiography predicts embolic events in infective endocarditis. *J Am Coll Cardiol* 2001;37:1069-76.
- Rohmann S, Erbel R, Darius H, Gorge G, Makowski T, Zotz R, Mohr-Kahaly S, Nixdorff U, Drexler M, Meyer J. Prediction of rapid versus prolonged healing of infective endocarditis by monitoring vegetation size. *J Am Soc Echocardiogr* 1991;4:465-74.
- Mügge A, Daniel WG, Frank G, Lichtlen PR. Echocardiography in infective endocarditis: re-assessment of prognostic implications of vegetation size determined by the transthoracic and the transoesophageal approach. *J Am Coll Cardiol* 1989;14:631-8.
- Mügge A. Management of imminent emboli in endocarditis: are they predictable? *Herz* 2001;26:391-7.
- Weinstein MP. Current blood culture methods and systems: clinical concepts, technology, and interpretation of results. *Clin Infect Dis* 1996; 23:40-6.
- Shah PM, Ullmann U, Seifert H, Trautmann M, Briedigkeit H, Gross RJ, Jansen B, Kern WV, Reinert RR, Rosenthal EJK, Roth B, Salzberger B, Schrappe M, Spencker FB, von Stockhausen HB, Steinmetz T, A'Asi J. Sepsis-Blutkulturdiagnostik. *MiQ* 1997;3:1-44.
- Morris AJ, Drinkovic D, Pottumarthy S, Strickert MG, MacCulloch D, Lambie N, Kerr AR. Gram stain, culture, and histopathological examination findings for heart valves removed because of infective endocarditis. *Clin Infect Dis* 2003;36:697-704.
- Chuard C, Antley CM, Reller LB. Clinical utility of cardiac valve Gram stain and culture in patients undergoing native valve replacement. *Arch Pathol Lab Med* 1998;122:412-5.
- Brouqui P, Raoult D. Endocarditis due to rare and fastidious bacteria. *Clin Microbiol Rev* 2001;14:177-207.
- Goldenberger D, Kunzli A, Vogt P, Zbinden R, Altwegg M. Molecular diagnosis of bacterial endocarditis by broad-range PCR amplification and direct sequencing. *J Clin Microbiol* 1997;35:2733-9.
- Lisby G, Gutschik E, Durack DT. Molecular methods for diagnosis of infective endocar-

- ditis. *Infect Dis Clin North Am* 2002;16:393-412.
24. Bosshard PP, Kronenberg A, Zbinden R, Ruef C, Bottger EC, Altwegg M. Etiologic diagnosis of infective endocarditis by broad-range polymerase chain reaction: a 3-year experience. *Clin Infect Dis* 2003;37:167-72.
 25. Millar B, Moore J, Mallon P, Xu J, Crowe M, Mcclurg R, Raoult D, Earle J, Hone R, Murphy P. Molecular diagnosis of infective endocarditis – a new Duke's criterion. *Scand J Infect Dis* 2001;33:673-80.
 26. Lepidi H, Durack DT, Raoult D. Diagnostic methods current best practices and guidelines for histologic evaluation in infective endocarditis. *Infect Dis Clin North Am* 2002;16:339-61, ix.
 27. Murdoch DR. Diagnosis of Legionella infection. *Clin Infect Dis* 2003;36:64-9.
 28. Durack DT, Lukes AS, Bright DK. New criteria for diagnosis of infective endocarditis: utilization of specific echocardiographic findings. Duke Endocarditis Service. *Am J Med* 1994;96:200-9.
 29. Naber CK, Erbel R. Diagnosis of culture negative endocarditis: novel strategies to prove the suspect guilty. *Heart* 2003;89:241-3.
 30. Habib G, Derumeaux G, Avierinos JF, Casalta JP, Jamal F, Volot F, Garcia M, Lefevre J, Biou F, Maximovitch-Rodaminoff A, Fournier PE, Ambrosi P, Velut JG, Cribier A, Harle JR, Weiller PJ, Raoult D, Luccioni R. Value and limitations of the Duke criteria for the diagnosis of infective endocarditis. *J Am Coll Cardiol* 1999;33:2023-9.
 31. Kupferwasser LI, Darius H, Muller AM, Martin C, Mohr-Kahaly S, Erbel R, Meyer J. Diagnosis of culture-negative endocarditis: the role of the Duke criteria and the impact of transesophageal echocardiography. *Am Heart J* 2001;142:146-52.
 32. Rognon R, Kehtari R, Francioli P. Individual value of each of the Duke criteria for the diagnosis of infective endocarditis. *Clin Microbiol Infect* 1999;5:396-403.
 33. Uh Y, Shin DH, Jang IH, Hwang GY, Lee MK, Yoon KJ, Kim HY. Antimicrobial susceptibility patterns and macrolide resistance genes of viridans group streptococci from blood cultures in Korea. *J Antimicrob Chemother* 2004;53:1095-7.
 34. Stein DS, Nelson KE. Endocarditis due to nutritionally deficient streptococci: therapeutic dilemma. *Rev Infect Dis* 1987;9:908-16.
 35. Karchmer AW, Moellering RC, Jr., Maki DG, Swartz MN. Single-antibiotic therapy for streptococcal endocarditis. *JAMA* 1979;241:1801-6.
 36. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. *JAMA* 1992;267:264-7.
 37. Wilson WR, Thompson RL, Wilkowske CJ, Washington JA, Giuliani ER, Geraci JE. Short-term therapy for streptococcal infective endocarditis. Combined intramuscular administration of penicillin and streptomycin. *JAMA* 1981;245:360-3.
 38. Sexton DJ, Tenenbaum MJ, Wilson WR, Steckelberg JM, Tice AD, Gilbert D, Dismukes W, Drew RH, Durack DT. Ceftriaxone once daily for four weeks compared with ceftriaxone plus gentamicin once daily for two weeks for treatment of endocarditis due to penicillin-susceptible streptococci. Endocarditis Treatment Consortium Group. *Clin Infect Dis* 1998;27:1470-4.
 39. Malakoff RF, Frank E et al Streptococcal endocarditis: single vs combination therapy *JAMA* 1979;241:1807-10.
 40. Tan JS, Kaplan S, Terhune CA Jr, Hamburger M. Successful two week schedule for penicillin-susceptible *S. viridans* endocarditis. *Lancet* 1971;2:1340-3.
 41. Roberts SA, Lang SR. Short course treatment of penicillin-susceptible viridans streptococcal endocarditis with penicilline and gentamicin. *Inf Dis Clin Pract* 1993;2:191-4.
 42. Woolfe JC, Johnson WD Penicilline-sensitive streptococcal endocarditis: in vitro and clinical observations on penicillin-streptomycin therapy *Ann Int Med* 1974;81:178-81.
 43. Perillo JE, Porst, MH et al Endocarditis due to resistant viridans streptococci during dental penicillin prophylaxis *NEJM* 1979;300:296-300.
 44. Friedberg LK, Rosen KM et al Vancomycin therapy for enterococcal and *S. viridans* endocarditis. *Arch Int Med* 1968;122:134.
 45. Wilson AP, Gaya H Treatment of endocarditis with teicoplanin: a retrospective analysis of 104 cases *J Antimicrob Chemother* 1996;38:507-21.
 46. Presterl E, Graninger W, Georgopoulos A. The efficacy of teicoplanin in the treatment of endocarditis caused by gram-positive bacteria. *J Antimicrob Chemother* 1992;31:755-766.
 47. Kresken M, Hafner D. Drug resistance among clinical isolates of frequently encountered bacterial species in central Europe during 1975-1995. Study Group Bacterial Resistance of the Paul-Ehrlich-Society for Chemotherapy. *Infection* 1999;27(Suppl 2):S2-8.
 48. Fruden TR, Munruff SS. Emergence of vancomycin-resistant endocarditis in New York City. *Lancet* 1993;342:76.
 49. Babcock HM, Ritchie DJ, Christiansen E, Starlin R, Little R, Stanley S. Successful treatment of vancomycin-resistant Enterococcus endocarditis with oral linezolid. *Clin Infect Dis* 2001;32:1373-5.
 50. Thompson RL, Lavin B, Talbot GH. Endocarditis due to vancomycin-resistant Enterococcus faecium in an immunocompromised patient: cure by administering combination therapy with quinupristin/dalfopristin and high-dose ampicillin. *South Med J* 2003;96:818-20.
 51. Patterson JE, Sweeney AH, Simms M, Carley N, Mangi R, Sabetta J, Lyons RW. An analysis of 110 serious enterococcal infections. Epidemiology, antibiotic susceptibility, and outcome. *Medicine (Baltimore)* 1995;74:191-200.
 52. Wilson WR, Wilkowske CJ et al Treatment of streptomycin susceptible and streptomycin resistant enterococcal endocarditis. *Ann Int Med* 1984;100:816-23.
 53. Schmit, JL Efficiency of teicoplanin for enterococcal infection: 63 cases and review. *Clin Infect Dis* 1992;15:302-6.
 54. Westenfelder GO, Peterson PJ et al Vancomycin-streptomycin synergism in enterococcal endocarditis. *JAMA* 1973;223:37-40.
 55. Chambers HF, Korzeniowski OM, Sande MA. Staphylococcus aureus endocarditis: clinical manifestations in addicts and nonaddicts. *Medicine (Baltimore)* 1983;62:170-7.
 56. Witte W, Bralke C, Cuny C, Heuck D, Kresken M. Changing pattern of antibiotic resistance in methicillin-resistant Staphylococcus aureus from German hospitals. *Infect Control Hosp Epidemiol* 2001;22:683-6.
 57. Staphylococcus aureus resistant to vancomycin – United States, 2002. *MMWR Morb Mortal Wkly Rep* 2002;51:565-7.
 58. Small PM, Chambers HF. Vancomycin for Staphylococcus aureus endocarditis in intravenous drug users. *Antimicrob Agents Chemother* 1990;34:1227-31.
 59. Korzeniowski O, Sande MA. Combination antimicrobial therapy for Staphylococcus aureus endocarditis in patients addicted to parenteral drugs and in nonaddicts: A prospective study. *Ann Intern Med* 1982;97:496-503.
 60. Karchmer AW, Archer GL, Dismukes WE. Rifampin treatment of prosthetic valve endocarditis due to Staphylococcus epidermidis. *Rev Infect Dis* 1983;5(Suppl 3):S543-8.
 61. Archer GL, Johnston JL, Vazquez GJ, Haywood HB, III. Efficacy of antibiotic combinations including rifampin against methicillin-resistant Staphylococcus epidermidis: in vitro and in vivo studies. *Rev Infect Dis* 1983;5(Suppl 3):S538-42.
 62. Lucet JC, Herrmann M, Rohner P, Auckenthaler R, Waldvogel FA, Lew DP. Treatment of experimental foreign body infection caused by methicillin-resistant Staphylococcus aureus. *Antimicrob Agents Chemother* 1990;34:2312-7.
 63. Rouse MS, Wilcox RM, Henry NK, Steckelberg JM, Wilson WR. Ciprofloxacin therapy of experimental endocarditis caused by methicillin-resistant Staphylococcus epidermidis. *Antimicrob Agents Chemother* 1990;34:273-6.
 64. Karchmer AW, Archer GL, Dismukes WE. Staphylococcus epidermidis causing prosthetic valve endocarditis: microbiological and clinical observations as guides to therapy. *Ann Int Med* 1983;98:447-53.
 65. Vandenesch F, Etienne J, Reverdy ME, Eykyn SJ. Endocarditis due to Staphylococcus lugdunensis: report of 11 cases and review. *Clin Infect Dis* 1993;17:871-6.
 66. Wilson WR, Karchmer AW, Dajani AS, Taubert KA, Bayer A, Kaye D, Bisno AL, Ferrieri P, Shulman ST, Durack DT. Antibiotic treatment of adults with infective endocarditis due to streptococci, enterococci, staphylococci, and HACEK microorganisms. American Heart Association. *JAMA* 1995;274:1706-13.
 67. Wieland M, Lederman MM, Kline-King C, Keys TF, Lerner PI, Bass SN, Chmielewski R, Banks VD, Ellner JJ. Left-sided endocarditis due to Pseudomonas aeruginosa. A report of 10 cases and review of the literature. *Medicine (Baltimore)* 1986;65:180-9.
 68. Reyes MP, Brown WJ, Lerner AM. Treatment of patients with pseudomonas endocarditis with high dose aminoglycoside and carbenicillin therapy. *Medicine (Baltimore)* 1978;57:57-67.
 69. Fantin B, Farinotti R, Thabaut A, Carbon C. Conditions for the emergence of resistance to ceftiofime and ceftazidime in experimental endocarditis due to Pseudomonas aeruginosa. *J Antimicrob Chemother* 1994;33:563-9.
 70. Pefanis A, Giamarellou H, Karayiannakos P, Donta I. Efficacy of ceftazidime and aztreonam alone or in combination with amikacin in experimental left-sided Pseudomonas aeruginosa endocarditis. *Antimicrob Agents Chemother* 1993;37:308-13.
 71. Geraci JE, Wilson WR. Symposium on infective endocarditis. III. Endocarditis due to gram-negative bacteria. Report of 56 cases. *Mayo Clin Proc* 1982;57:145-8.
 72. Ellis ME, Al Abdely H, Sandridge A, Greer W, Ventura W. Fungal endocarditis: evidence in the world literature, 1965-1995. *Clin Infect Dis* 2001;32:50-62.
 73. Donal E, Abgueguen P, Coisne D, Gouello JP, McFadden EP, Alal J, Corbi P. Echocardiogra-

- phic features of *Candida* species endocarditis: 12 cases and a review of published reports. *Heart* 2001;86:79-182.
74. Muehrcke DD, Lytle RW. Surgical and long term antifungal therapy for fungal prosthetic valve endocarditis. *Ann Thorac Surg* 1995;60:538-43.
 75. Duroux-Vouilloz C, Praz G, Francioli P, Peter O. Q-fever endocarditis, clinical presentation and serological follow-up of 21 patients. *SMW* 1998;128:740-4.
 76. Jacobs F, Abramowicz D, Vereerstraeten P, Le Clerc JL, Zech F, Thys JP. Brucella endocarditis: the role of combined medical and surgical treatment. *Rev Infect Dis* 1990;12:740-4.
 77. Raoult D, Fournier PE, Drancourt M, Marrie TJ, Etienne J, Cosserrat J, Cacoub P, Poincignon Y, Leclercq P, Sefton AM. Diagnosis of 22 new cases of Bartonella endocarditis. *Ann Intern Med* 1996;125:646-52.
 78. Siegman-Igra Y, Kaufman O, Keysary A, Rztokiewicz S, Shalit I. Q-fever endocarditis in Israel and a world wide review. *Scand J Infect Dis* 1997;29:41-9.
 79. Sanchez-Recalde A, Mate I, Lopez E, Yebra M, Merino JL, Perea J, Tellez A, Sobrino JA. *Coxiella burnetii* endocarditis: long-term clinical course in 20 patients. *Rev Espanol Cardiol* 2000;53:940-6.
 80. Drancourt M, Mainardi JL, Brouqui P, Vandenesch F, Carta A, Lehnert F, Etienne J, Goldstein F, Acar J, Raoult D. Bartonella (Rochalimaea) quintana endocarditis in three homeless men. *N Engl J Med* 1995;332:419-23.
 81. Raoult D. Afebrile blood culture-negative endocarditis. *Ann Intern Med* 1999;131:144-6.
 82. Saravolatz LD, Burch KH, Quinn EL, Cox F, Madhavan T, Fisher E. Polymicrobial infective endocarditis: an increasing clinical entity. *Am Heart J* 1978;95:163-8.
 83. Chambers HF, Miller RT, Newman MD. Right-sided *Staphylococcus aureus* endocarditis in intravenous drug abusers: two-week combination therapy. *Ann Intern Med* 1988;109:619-24.
 84. Ribera E, Gomez-Jimenez J, Cortes E, del Valle O, Planes A, Gonzalez-Alujas T, Almirante B, Ocana I, Pahissa A. Effectiveness of cloxacillin with and without gentamicin in short-term therapy for right-sided *Staphylococcus aureus* endocarditis. A randomized, controlled trial. *Ann Intern Med* 1996;125:969-74.
 85. Heldman AW, Hartert TV, Ray SC, Daoud EG, Kowalski TE, Pompili VJ, Sisson SD, Tidmore WC, vom Eigen KA, Goodman SN, Lietman PS, Petty BG, Flexner C. Oral antibiotic treatment of right-sided staphylococcal endocarditis in injection drug users: prospective randomized comparison with parenteral therapy. *Am J Med* 1996;101:68-76.
 86. Niebel J. Infective endocarditis in immunocompromised patients. In: Horstkotte D, Bodnar E, editors. *Current issues in heart valve disease: infective endocarditis*. London: ICR Publishers, 1991:154-63.
 87. Nahass RG, Weinstein MP, Bartels J, Gocke DJ. Infective endocarditis in intravenous drug users: a comparison of human immunodeficiency virus type 1-negative and -positive patients. *J Infect Dis* 1990;162:967-70.
 88. Pulvirenti JJ, Kerns E, Benson C, Lisowski J, Demarais P, Weinstein RA. Infective endocarditis in injection drug users: importance of human immunodeficiency virus serostatus and degree of immunosuppression. *Clin Infect Dis* 1996;22:40-5.
 89. Francioli P, Etienne J, Hoigne R, Thys JP, Gerber A. Treatment of streptococcal endocarditis with a single daily dose of ceftriaxone sodium for 4 weeks. Efficacy and outpatient treatment feasibility. *JAMA* 1992;267:264-7.
 90. Stambouliau D, Bonvehi P, Arevalo C, Bologna R, Cassetti I, Scilingo V, Efron E. Antibiotic management of outpatients with endocarditis due to *Staphylococcus aureus*: deleterious effect of anticoagulant therapy. *Arch Intern Med* 1999;159:473-5.
 91. Tornos P, Almirante B, Mirabet S, Permanyer G, Pahissa A, Soler-Soler J. Infective endocarditis due to *Staphylococcus aureus*: deleterious effect of anticoagulant therapy. *Arch Intern Med* 1999;159:473-5.
 92. Chan KL, Dumesnil JG, Cujec B, Sanfilippo AJ, Jue J, Turek MA, Robinson TI, Moher D; Investigators of the Multicenter Aspirin Study in Infective Endocarditis. A randomized trial of aspirin on the risk of embolic events in patients with infective endocarditis. *J Am Coll Cardiol* 2003;42:775-80.
 93. Netzer RO, Altwegg SC, Zollinger E, Tauber M, Carrel T, Seiler C. Infective endocarditis: determinants of long term outcome. *Heart* 2002;88:61-6.
 94. Dellinger RP, Carlet JM, Masur H, Gerlach H, Calandra T, Cohen J, Gea-Banacloche J, Keh D, Marshall JC, Parker MM, Ramsay G, Zimmerman JL, Vincent JL, Levy MM; Surviving Sepsis Campaign Management Guidelines Committee. Surviving Sepsis Campaign guidelines for management of severe sepsis and septic shock. *Crit Care Med* 2004;32:858-73.
 95. DiDomenico RJ, Park HY, Southworth MR, Eyrich HM, Lewis RK, Finley JM, Schumock GT. Guidelines for acute decompensated heart failure treatment. *Ann Pharmacother* 2004;38:649-60.
 96. Graupner C, Vilacosta I, SanRoman J, Ronderos R, Sarria C, Fernandez C, Mujica R, Sanz O, Sanmartin JV, Pinto AG. Periannular extension of infective endocarditis. *J Am Coll Cardiol* 2002;39:1204-11.
 97. Choussat R, Thomas D, Isnard R, Michel PL, Iung B, Hanania G, Mathieu P, David M, du Roy C, de Gevigney G, Le Breton H, Logeais Y, Pierre-Justin E, de Riberolles C, Morvan Y, Bischoff N. Perivalvular abscesses associated with endocarditis; clinical features and prognostic factors of overall survival in a series of 233 cases. Perivalvular Abscesses French Multicentre Study. *Eur Heart J* 1999;20:232-41.
 98. Rohmann S, Seifert T, Erbel R, Jakob H, Mohr-Kahaly S, Makowski T, Gorge G, Oelert H, Meyer J. Identification of abscess formation in native-valve infective endocarditis using transesophageal echocardiography: implications for surgical treatment. *Thorac Cardiovasc Surg* 1991;18:353-9.
 99. Chan KL. Early clinical course and long-term outcome of patients with infective endocarditis complicated by perivalvular abscess. *CMAJ* 2002;167:19-24.
 100. Rohmann S, Erbel R, Darius H, Makowski T, Meyer J. Effect of antibiotic treatment on vegetation size and complication rate in infective endocarditis. *Clin Cardiol* 1997;20:132-40.
 101. Vilacosta I, Graupner C, San Roman JA, Sarria C, Ronderos R, Fernandez C, Mancini L, Sanz O, Sanmartin JV, Stoermann W. Risk of embolization after institution of antibiotic therapy for infective endocarditis. *J Am Coll Cardiol* 2002;39:1489-95.
 102. Empfehlungen der ständigen Impfkommission am Robert Koch Institut (STIKO). <http://www.rki.de/>
 103. Horstkotte D, Schulte HD, Niehues R, Klein RM, Piper C, Strauer BE. Diagnostic and therapeutic considerations in acute, severe mitral regurgitation: experience in 42 consecutive patients entering the intensive care unit with pulmonary edema. *J Heart Valve Dis* 1993;2:212-22.
 104. Horstkotte D, Piper C, Wiemer M, Arendt G, Steinmetz H, Bergemann R, Schulte HD, Schultheiß HP. Emergency heart valve replacement after acute cerebral embolism during florid endocarditis. *Med Klin* 1998;15:284-93.
 105. Chastre J, Trouillet JL. Early infective endocarditis on prosthetic valves. *Eur Heart J* 1995;16(Suppl B):32-8.
 106. Piper C, Körfer R, Horstkotte D. Prosthetic valve endocarditis. *Heart* 2001;85:590-3.
 107. Hagl C, Galla JD, Lansman SL, Fink D, Bodian CA, Spielvogel D, Griep RB. Replacing the ascending aorta and aortic valve for acute prosthetic valve endocarditis: is using prosthetic material contraindicated? *Ann Thorac Surg* 2002;74:S1781-5.
 108. Lytle BW, Sabik JF, Blackstone EH, Svensson LG, Petterson GB, Cosgrove DM, III. Reoperative cryopreserved root and ascending aorta replacement for acute aortic prosthetic valve endocarditis. *Ann Thorac Surg* 2002;74:S1754-7.